Orchard Therapeutics PLC
Sheila Gilbride-Wilson has held various leadership positions in clinical operations throughout their career. Sheila started as a Clinical Research Associate at Pfizer, Inc. in 1986 and worked their way up to Vice President roles at different companies such as Vertex Pharmaceuticals, ePharmaSolutions, and Proteostasis Therapeutics, Inc. Sheila provided strategic guidance in clinical operations, data management, compliance, and team development in the pharmaceutical industry. Most recently, they served as the Vice President of Clinical Operations and Data Management at Orchard Therapeutics, overseeing clinical trials in ultra-rare disease gene therapy. Throughout their career, they have demonstrated a strong ability to lead teams and manage resources effectively.
Sheila Gilbride-Wilson obtained their Bachelor of Science in Registered Nursing/Registered Nurse from City University of New York-Herbert H. Lehman College. Subsequently, they earned an MBA in Pharmaceutical Marketing from Saint Joseph's University - Erivan K. Haub School of Business. Additionally, they have a certification in Strategies and Leadership from the Massachusetts Institute of Technology.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.